When cancer reaches bone, the consequences can be devastating: pain, fractures, loss of movement, and sometimes death. To understand how that journey happens—and how to stop it—researchers build living models of it. Cancer spread is a major cause of death in several cancers, including breast, prostate, and thyroid cancers.

Bone is one of the most common places cancer spreads, so treating cancer in bone is crucial for a cure. Disease models are needed to understand how cancer spreads to bone and to develop treatments. Several kinds of models exist, but a collection covering different bone-spreading cancers has not been available.

This review compiles animal models from current bone-spread experiments, mostly involving breast and prostate cancer, to improve early treatment research and support better care for bone metastasis. Animal models have been used to explore how cancer spreads and what its spread may mean for a patient.

They have also been used to study advanced disease, find possible protein targets, and develop treatments aimed at metastasis. But fully reproducing human bone metastasis in an animal is difficult. Different cancer cells, animals, and ways of introducing tumors can still build models suited to different questions.

The central idea is that no single model can represent all the genetic mechanisms of bone metastasis. It is like trying to understand an entire city by studying only one street: the street can teach you something real, but not everything happening across the city.

Because bone metastasis involves the whole body, no single model can represent all its genetic mechanisms, so the review gathers a selection of animal models to assist future studies. Because no single animal can capture every way cancer spreads to bone, researchers combine different animals, cancer cells, injection approaches, and follow-up tests.

This picture matters because choosing among these options determines which parts of the disease a study can realistically reproduce. Introducing cancer cells into their original kind of tissue best reproduces the process of cancer metastasis in the human body. From there, tumor cells can enter blood vessels and travel toward target organs.

In breast cancer animal models, this approach achieves bone metastases in forty to sixty percent of cases. It therefore lets researchers study cancer spreading from a starting site rather than placing the cells directly where they will end up. Another approach places tumor cells directly into the bloodstream through the heart.

The cells then attach, break through surrounding material, and move before causing metastases in different organs, simulating spread through the blood. This heart-injection approach has become preferred for studying factors that regulate bone metastasis.

Its drawback is relatively high death after the procedure, although practice can raise survival above ninety percent. Researchers can attach light-producing or fluorescent labels to cancer cells. Those labels allow tumor development in the bones of living animals to be monitored over time.

This makes it possible to follow where tumors and metastases appear without relying only on what can be seen after the animal is examined. Animal models are vital tools in early treatment research because they can help identify key steps in bone metastasis. Most tests have used cancer-cell injection models, which are effective for studying interactions between cancer cells and the bone environment.

These models cannot study the early stages of bone metastasis, so they do not capture those earliest steps in disease development. They often use immunodeficient animals, allowing xenografted tumors to grow without eliciting a normal host immune response or triggering rejection.

The final warning is important: mice have limitations when they are used to study human tumor immunity. Differences between human and animal pathways can help explain why a treatment that succeeds before human testing is not perfectly successful in people.

These models let researchers study how cancer cells reach and interact with bone, but no single model captures the whole human disease. That matters because a treatment that works in a mouse may still fail in people.